Fosaprepitant dimeglumine/palonosetron hydrochloride - Beihai Biotech
Alternative Names: BH-006; Palonosetron hydrochloride/fosaprepitant dimeglumine - Beihai BiotechLatest Information Update: 29 Jul 2022
At a glance
- Originator Beihai Biotech
- Class Antiemetics; Fluorinated hydrocarbons; Isoquinolines; Morpholines; Phosphinic acids; Phosphonic acids; Quinuclidines; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Serotonin 3 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chemotherapy-induced nausea and vomiting
Most Recent Events
- 17 Jun 2022 Fosaprepitant dimeglumine/palonosetron hydrochloride - Beihai Biotech is available for licensing as of 16 Jun 2022. http://www.bayhibiotech.com/page115
- 06 Apr 2022 The Center for Drug Evaluation (CDE) of the State Drug Administration accepts clinical trial application of BH 006 in Chemotherapy-induced nausea and vomiting
- 06 Apr 2022 Beihai Biotech plans clinical trial in Chemotherapy-induced nausea and vomiting in China